Quest Diagnostics (DGX) CEO James E. Davis exercises options and sells common stock

Q: What insider transaction did Quest Diagnostics (DGX) report for its CEO?

Quest Diagnostics reported that CEO and President James E. Davis exercised a non-qualified stock option for 55,093 shares at an exercise price of $95.795 per share on 11/25/2025 , then sold shares in multiple transactions the same day.

Q: How many Quest Diagnostics (DGX) shares did the CEO sell on 11/25/2025 and at what prices?

On 11/25/2025 , James E. Davis reported sales of 9,342 shares at a weighted average price of $191.5888 , 41,004 shares at $192.2715 , and 4,747 shares at $192.9717 , each executed in multiple trades within stated price ranges.

Q: How many Quest Diagnostics (DGX) shares does the CEO own after the reported Form 4 transactions?

Following the exercise and sales reported on 11/25/2025 , James E. Davis directly owned 120,480 shares of Quest Diagnostics common stock.

Q: What was the nature of the stock option exercised by the Quest Diagnostics (DGX) CEO?

The derivative security was a non-qualified stock option (right to buy) for 55,093 shares of common stock with an exercise price of $95.795 per share. It had an expiration date of 02/21/2027 and vested in three equal annual installments beginning on the first anniversary of the grant date.

Q: Why are price ranges mentioned for the Quest Diagnostics (DGX) insider stock sales?

The filing notes each sale transaction was executed in multiple trades within specified price ranges, and the reported prices are weighted average sale prices . The reporting person undertakes to provide full trade details upon request to the SEC staff, the issuer, or any security holder.

Filing Impact

(Very High)

Filing Sentiment

(Very Negative)

Form Type

Rhea-AI Filing Summary

Quest Diagnostics CEO and President James E. Davis reported an option exercise and related stock sales. On 11/25/2025, he exercised a non-qualified stock option to buy 55,093 shares of common stock at an exercise price of $95.795 per share, increasing his direct holdings to 175,573 shares immediately after the exercise.

That same day, he sold shares in several market transactions under a pre-arranged Rule 10b5-1 sales plan. These sales included 9,342 shares at a weighted average price of $191.5888, 41,004 shares at $192.2715, and 4,747 shares at $192.9717, each executed in multiple trades within disclosed price ranges. After these transactions, Davis directly owned 120,480 shares of Quest Diagnostics common stock, and the reported stock option grant showed 0 options remaining following the exercise.

Insider Trade Summary

Net Seller: 55,093 shares ($10,589,760)

Net Sell 5 txns

Insider Davis J. E.

Role CEO and President

Sold 55,093 shs ($10.59M)

Type	Security	Shares	Price	Value
Exercise	Non-Qualifed Stock Option (right to buy)	55,093	$95.795	$5.28M
Exercise	Common Stock	55,093	$95.795	$5.28M
Sale	Common Stock	9,342	$191.5888	$1.79M
Sale	Common Stock	41,004	$192.2715	$7.88M
Sale	Common Stock	4,747	$192.9717	$916K

Holdings After Transaction: Non-Qualifed Stock Option (right to buy) — 0 shares (Direct); Common Stock — 175,573 shares (Direct)

Footnotes (1)

This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. This transaction was executed in multiple trades at prices ranging from $190.810 to $191.805. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $191.820 to $192.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $192.820 to $193.310. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.

Form 4 Insider Transactions: What Each Field Means →

11/28/2025 - 04:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis J. E.

(Last)

(First)

(Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS

07094

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/25/2025		M⁽¹⁾		55,093	A	$95.795	175,573	D
Common Stock	11/25/2025		S⁽¹⁾		9,342	D	$191.5888⁽²⁾	166,231	D
Common Stock	11/25/2025		S⁽¹⁾		41,004	D	$192.2715⁽³⁾	125,227	D
Common Stock	11/25/2025		S⁽¹⁾		4,747	D	$192.9717⁽⁴⁾	120,480	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualifed Stock Option (right to buy)	$95.795	11/25/2025		M⁽¹⁾			55,093	⁽⁵⁾	02/21/2027	Common Stock	55,093	$95.795	0	D

Explanation of Responses:

1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $190.810 to $191.805. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $191.820 to $192.810. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $192.820 to $193.310. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.

Remarks:

	Sean D. Mersten, Attorney in Fact for James E. Davis	11/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Quest Diagnostics (DGX) report for its CEO?

Quest Diagnostics reported that CEO and President James E. Davis exercised a non-qualified stock option for 55,093 shares at an exercise price of $95.795 per share on 11/25/2025, then sold shares in multiple transactions the same day.

How many Quest Diagnostics (DGX) shares did the CEO sell on 11/25/2025 and at what prices?

On 11/25/2025, James E. Davis reported sales of 9,342 shares at a weighted average price of $191.5888, 41,004 shares at $192.2715, and 4,747 shares at $192.9717, each executed in multiple trades within stated price ranges.

How many Quest Diagnostics (DGX) shares does the CEO own after the reported Form 4 transactions?

Following the exercise and sales reported on 11/25/2025, James E. Davis directly owned 120,480 shares of Quest Diagnostics common stock.

What was the nature of the stock option exercised by the Quest Diagnostics (DGX) CEO?

The derivative security was a non-qualified stock option (right to buy) for 55,093 shares of common stock with an exercise price of $95.795 per share. It had an expiration date of 02/21/2027 and vested in three equal annual installments beginning on the first anniversary of the grant date.

Were the Quest Diagnostics (DGX) CEO’s stock sales under a Rule 10b5-1 plan?

Yes. The filing states that the exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person, which is a pre-arranged trading plan for insiders.

Why are price ranges mentioned for the Quest Diagnostics (DGX) insider stock sales?

The filing notes each sale transaction was executed in multiple trades within specified price ranges, and the reported prices are weighted average sale prices. The reporting person undertakes to provide full trade details upon request to the SEC staff, the issuer, or any security holder.